Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.00    -0.40 (-0.61%)
Bid:
65.00
Ask:
65.50
Spread: 0.50 (0.769%)
Market Cap: £574.23m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Appointment of Chairman; Board changes

17 Sep 2018 07:00

RNS Number : 9280A
IP Group PLC
17 September 2018
 

FOR RELEASE ON

17 September 2018

 

IP Group plc - Appointment of Sir Douglas Flint as Non-Executive Chairman; Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, is delighted to announce the appointment of Sir Douglas Flint, CBE as Non-executive Chairman and Director of the Company. Sir Douglas has initially been appointed as Chairman-Elect with effect from today and will assume the role of Chairman with effect from 01 November 2018.

 

Sir Douglas will replace Mike Humphrey who, as the Group announced in May, had indicated that, for personal reasons, he wished to retire and step down from the position of Non-executive Chairman and Director of the Company as soon as a suitable replacement was found. Accordingly, Mr Humphrey will step down from the IP Group Board at the close of business on 31 October 2018.

 

Sir Douglas retired as Group Chairman of HSBC Holdings plc on 30th September 2017, having been appointed to that role in December 2010. For fifteen years prior to this he was HSBC's Group Finance Director, joining from KPMG where he was a partner. Between 2005 and 2011 he was also a Non-Executive Director of BP plc. Mr Flint was Chairman of the Institute of International Finance from June 2012 to December 2016 and was a member of both the Mayor of Beijing's and the Mayor of Shanghai's International Business Leaders' Advisory Councils. Amongst other roles he is currently Chairman of the Archbishop of Canterbury's Just Finance Foundation, a Director of the Centre for Policy Studies, on the Global Advisory Council of Motive Partners, a fintech specialist investment platform, Chairman of the Corporate Board of Cancer Research UK and a Trustee of the Royal Marsden Cancer Charity. In December 2017 he was appointed by the Chancellor as Special Envoy to China's Belt and Road Initiative.

 

In addition, IP Group confirms that Professor Lynn Gladden will step down from the IP Group Board at the close of business on 30 September 2018. On 04 May 2018, the Group announced that Professor Gladden had been appointed to the role of Executive Chairman of the Engineering and Physical Sciences Research Council (EPSRC) with effect from 1 October 2018 and, as such, was required to step down from her role at IP Group on or before 31 December 2018 to avoid any potential conflict of interest.

 

Sir Douglas Flint said: "I have long been fascinated by how to develop fully the exciting commercial opportunities that emerge from research developed within the world's leading academic institutions and I'm excited to be given the opportunity to chair one of the leading companies focused on backing and building world-changing businesses based on innovative science and technology. I'm very impressed with IP Group's business model and am looking forward to working with the team to help deliver value for all stakeholders".

 

Alan Aubrey, Chief Executive of IP Group, said: "I am delighted to welcome Sir Douglas to the Board. He is one of most respected directors in the FTSE 100 with a wealth of highly relevant experience. The Group will benefit enormously from his expertise and we look forward to working with him at this exciting point in IP Group's development. I would also like to reiterate the Board's thanks to both Mike Humphrey and Professor Lynn Gladden for their counsel and contribution to IP Group."

 

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other details required to be disclosed under Listing Rule 9.6.13R. There are no further disclosures required under the Disclosure and Transparency Rules. Sir Douglas currently owns 2,400 ordinary shares in IP Group.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOALFMMTMBTBTLP
Date   Source Headline
11th Jun 20267:00 amRNSHolding(s) in Company
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.